Triple agonists add glucagon receptor activation, which: Increases resting energy expenditure by 8% to 12% (Jall et al., Diabetes Care 2024) Promotes hepatic fat oxidation and reduces steatosis May offset some of the lean mass loss seen with GLP-1 monotherapy (early signal, not yet confirmed in long-term trials) The weight loss ceiling for retatrutide appears to be 24% to 26% based on phase 3 data, though long-term real-world outcomes are not yet available
After you eat (and your blood sugar increases), GLP-1 medications work by helping your body make more insulin while secreting less glucagon
Lean proteins, such as chicken breast, tofu, or Greek yogurt, and protein powders, are ideal for semaglutide users to meet their protein needs
Dadka waaweyn waxay qaataan 2-3g maalintiiba 2-3 qiyaasood
Appetite Regulation and Satiety Enhancement One of the best-established research applications of cagrilintide involves appetite regulation and satiety signaling